참고문헌
- Euhus CJ, Ripley TR, Medina CG. The role of surgery for oligometastatic non-small cell lung cancer. Cancers (Basel) 2022;14:2524. https://doi.org/10.3390/cancers14102524
- Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022;20:497-530. https://doi.org/10.6004/jnccn.2022.0025
- Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016;17:1672-82. https://doi.org/10.1016/S1470-2045(16)30532-0
- Yoo S, Cho WC, Lee GD, et al. Long-term surgical outcomes in oligometastatic non-small cell lung cancer: a single-center study. J Chest Surg 2023;56:25-32. https://doi.org/10.5090/jcs.22.101
- Tan AC, Tan DS. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol 2022;40:611-25. https://doi.org/10.1200/JCO.21.01626
- Al-Halabi H, Sayegh K, Digamurthy SR, et al. Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. J Thorac Oncol 2015;10:1601-7. https://doi.org/10.1097/JTO.0000000000000648
- Park BJ, Shim HS, Lee CY, et al. Genetic analysis and operative outcomes in patients with oncogene-driven advanced NSCLC treated with cytoreductive surgery as a component of local consolidative therapy. Cancers (Basel) 2021;13:2549. https://doi.org/10.3390/cancers13112549